Glasgow is UK lead in Pancreatic Cancer Research

A recent report has revealed that half of the top dozen UK pancreatic cancer researchers are based in Glasgow, with all six being affiliated with the University of Glasgow. The analysis, from, confirms Glasgow’s position as a leading centre of excellence for pancreatic cancer.

Central to this placement is the Glasgow Precision Oncology Laboratory, led by the University of Glasgow’s Professor Andrew Biankin, who leads a UK-wide flagship therapeutic development platform called Precision-Panc. The University uses a Precision Medicine approach to treating diseases like pancreatic cancer. Leading cancer charity Cancer Research UK has invested £10 million in the Precision-Panc platform.

Professor Andrew Biankin, founder of Precision-Panc, Regius Chair of Surgery and Director of the Wolfson Wohl Cancer Research Centre, within the Institute of Cancer Sciences at the University of Glasgow, commented: “What makes Glasgow unique in its ability to tackle pancreatic cancer is the fact we have clinicians and scientists working in close proximity on the same campus with a unified strategy – to create a critical mass for improving outcomes for people affected by pancreatic cancer.”

“Pancreatic cancer is a very aggressive disease, which remains difficult to treat. The University of Glasgow is at the forefront of developing new trials and treatment strategies for this devastating cancer, and these rankings confirm our world-leading position.”

First published: 30 July 2019